Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin + Paclitaxel in Metastatic Breast Cancer
NCT01156961Phase 4Withdrawn
- Sponsor
- Roche
- Start
- Oct 2010
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by Roche. Primary endpoint: Safety profile: Adverse events at 2 years. Planned start Oct 2010; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01156961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01156961.